EUVIMEDEUVIMED entdecken
Crossref

Cucurbitacin B attenuates LPS-induced skeletal muscle atrophy by inhibiting JAK2/STAT3 and suppressing proteasome activity

Sheng Cao, Xinzhe Liu, Yong Jin, Yi Tai, Jing Han, Shen Cao, Weiwei Zhong, Xinru Li, Yanjin Zheng, Yiming Huang, Yuedi Xiao, Yayun Cheng und 5 weitere

International Immunopharmacology · 2026-12 · 190 · 117499

DOI: 10.1016/j.intimp.2026.117499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Sheng Cao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, Jilin Pro…. Hauptthemen laut MEDLINE: Janus Kinase 2, STAT3 Transcription Factor, Triterpenes, Muscular Atrophy. Die Arbeit nennt 42 Literaturangaben. Gefördert von: The Education Department of Jilin Province, National Natural Science Foundation of China, Jilin Scientific and Technological Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Skeletal muscle atrophy results from an imbalance between protein synthesis and degradation, commonly driven by chronic inflammation. Cucurbitacin B (CuB), a natural tetracyclic triterpenoid with anti-inflammatory properties, has shown therapeutic promise in various inflammatory diseases, but its role in lipopolysaccharide (LPS)-induced muscle atrophy remains unexplored. PURPOSE: This study aimed to evaluate the therapeutic efficacy of CuB against LPS-induced skeletal muscle atrophy and to elucidate its multi-target mechanisms. METHODS: Network pharmacology was used to predict the core targets and signaling pathways of CuB against inflammatory skeletal muscle atrophy. In vitro, the effects of CuB on myogenic differentiation, anabolic signaling, markers of protein degradation, JAK/STAT3 signaling, and inflammatory cytokine expression were evaluated by Western blotting, immunofluorescence, H&E staining, and ELISA. In vivo, an LPS-induced mouse model of inflammatory muscle atrophy was established via intraperitoneal injection. Muscle phenotype, molecular mechanisms, and motor function were comprehensively assessed to evaluate the therapeutic potential of CuB. RESULTS: Network pharmacology predicted that CuB targets key nodes including AKT1, STAT3, and Src, and modulates the PI3K-Akt, FoxO, and insulin signaling pathways. In vitro, CuB alleviated C2C12 myotube atrophy and enhanced anabolic signaling via the IGF-1R/Akt/mTOR axis, while downregulating FoxO3a-mediated atrophy-related genes and reducing global protein ubiquitination, as well as modulating autophagy-related markers. Notably, compared with the specific JAK2 inhibitor AG490, CuB exhibited broader anti-atrophic efficacy. In vivo, CuB significantly ameliorated LPS-induced losses in muscle mass, fiber structure, grip strength, and locomotor activity. CONCLUSION: This study demonstrates that CuB alleviates LPS-induced skeletal muscle atrophy by promoting anabolic signaling and suppressing ubiquitin-proteasome pathway-related markers, while also modulating inflammatory responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2STAT3 Transcription FactorTriterpenesMuscular AtrophyProteasome Endopeptidase ComplexMuscle, SkeletalAnti-Inflammatory AgentsAnimalsLipopolysaccharidesMiceSignal TransductionMaleMice, Inbred C57BLCell Line

Stichwörter der Autor:innen

Cucurbitacin BLPSSkeletal muscle atrophy

Substanzen

Janus Kinase 2STAT3 Transcription FactorLipopolysaccharidesTriterpenesJak2 protein, mousecucurbitacin BStat3 protein, mouseProteasome Endopeptidase ComplexAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, Jilin Province, China; Key Laboratory of Drug Targets and Pharmacological Scree…
  • Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, Jilin Province, China.

Förderung

  • The Education Department of Jilin Province
  • National Natural Science Foundation of China
  • Jilin Scientific and Technological Development Program

Zitieren

APA

Cao, S., Liu, X., Jin, Y., Tai, Y., Han, J., Cao, S., Zhong, W., Li, X., Zheng, Y., Huang, Y., Xiao, Y., Cheng, Y., Xing, Y., Li, M. Y., Zuo, H. X., Ma, J., & Jin, X. (2026). Cucurbitacin B attenuates LPS-induced skeletal muscle atrophy by inhibiting JAK2/STAT3 and suppressing proteasome activity. International Immunopharmacology, 190, 117499. https://doi.org/10.1016/j.intimp.2026.117499

Vancouver

Cao S, Liu X, Jin Y, Tai Y, Han J, Cao S, et al. Cucurbitacin B attenuates LPS-induced skeletal muscle atrophy by inhibiting JAK2/STAT3 and suppressing proteasome activity. International Immunopharmacology. 2026;190:117499. doi:10.1016/j.intimp.2026.117499

BibTeX
@article{Cao2026,
  author = {Cao, Sheng and Liu, Xinzhe and Jin, Yong and Tai, Yi and Han, Jing and Cao, Shen and Zhong, Weiwei and Li, Xinru and Zheng, Yanjin and Huang, Yiming and Xiao, Yuedi and Cheng, Yayun and Xing, Yue and Li, Ming Yue and Zuo, Hong Xiang and Ma, Juan and Jin, Xuejun},
  title = {Cucurbitacin B attenuates LPS-induced skeletal muscle atrophy by inhibiting JAK2/STAT3 and suppressing proteasome activity},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {190},
  pages = {117499},
  doi = {10.1016/j.intimp.2026.117499}
}
Kostenlos starten →